Related references
Note: Only part of the references are listed.CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
Mohamad Hamieh et al.
NATURE (2019)
Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia
Linde M. Morsink et al.
BLOOD REVIEWS (2019)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
Jang Hwan Cho et al.
CELL (2018)
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A. Fraietta et al.
NATURE MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Activity of CAR19 T cells secreting impact fusion proteins against hematopoietic and solid tumors
Fay Dufort et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease
Katherine C. Pehlivan et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2018)
Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma
Jinhuan Xu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Universal CARs, universal T cells, and universal CAR T cells
Juanjuan Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
Stephanie Vairy et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
CAR22/19 Cocktail Therapy for Patients with Refractory/Relapsed B-Cell Malignancies
Liang Huang et al.
BLOOD (2018)
Neurological toxicities and coagulation disorders in the cytokine release syndrome during CAR-T therapy
Heng Mei et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
Chun-Meng Wang et al.
CLINICAL CANCER RESEARCH (2017)
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes
Carlos A. Ramos et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Frederick L. Locke et al.
MOLECULAR THERAPY (2017)
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Juliane Gust et al.
CANCER DISCOVERY (2017)
Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment
Zhenguang Wang et al.
PROTEIN & CELL (2017)
Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia
Karen Thudium Mueller et al.
BLOOD (2017)
Chimeric antigen receptor T-cell neuropsychiatric toxicity in acute lymphoblastic leukemia
Vasthie Prudent et al.
PALLIATIVE & SUPPORTIVE CARE (2017)
Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
Guoqing Wei et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2017)
Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells
K. Pinz et al.
LEUKEMIA (2016)
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Syed Abbas Ali et al.
BLOOD (2016)
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
Rebecca Gardner et al.
BLOOD (2016)
Chimeric antigen receptor T cell therapy: 25 years in the making
Saar Gill et al.
BLOOD REVIEWS (2016)
Targeted therapies for CLL: Practical issues with the changing treatment paradigm
Nitin Jain et al.
BLOOD REVIEWS (2016)
CD19-Targeted Chimeric Antigen Receptor-Modified T-Cell Immunotherapy for B-Cell Malignancies
C. J. Turtle et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
A review of monoclonal antibody therapies in lymphoma
Esmeralda Chi-yuan Teo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
Yongxian Hu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Driving CAR T-cells forward
Hollie J. Jackson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Toxicity and management in CAR T-cell therapy
Challice L. Bonifant et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies
Marco Ruella et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2016)
Impact of disease burden on long-term outcome of 19-28z CAR modified T cells in adult patients with relapsed B-ALL.
Jae Hong Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Tocilizumab-Refractory Cytokine Release Syndrome (CRS) Triggered By Chimeric Antigen Receptor (CAR)-Transduced T Cells May Have Distinct Cytokine Profiles Compared to Typical CRS
Kazusa Ishii et al.
BLOOD (2016)
Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
Stephan A. Grupp et al.
BLOOD (2016)
Engineered T cells: the promise and challenges of cancer immunotherapy
Andrew D. Fesnak et al.
NATURE REVIEWS CANCER (2016)
A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies
Maksim Mamonkin et al.
BLOOD (2015)
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs
Soranobu Ninomiya et al.
BLOOD (2015)
TRUCKs: the fourth generation of CARs
Markus Chmielewski et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
S. S. Kenderian et al.
LEUKEMIA (2015)
Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia
Quan-shun Wang et al.
MOLECULAR THERAPY (2015)
Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression
Kevin J. Curran et al.
MOLECULAR THERAPY (2015)
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Alfred L. Garfall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
Elena Sotillo et al.
CANCER DISCOVERY (2015)
Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia
Hanren Dai et al.
ONCOIMMUNOLOGY (2015)
IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia
H. J. Pegram et al.
LEUKEMIA (2015)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
CD123 AML targeting by chimeric antigen receptors A novel magic bullet for AML therapeutics?
Sarah Tettamanti et al.
ONCOIMMUNOLOGY (2014)
Adoptive Immunotherapy for Hematological Malignancies Using T Cells Gene-Modified to Express Tumor Antigen-Specific Receptors
Hiroshi Fujiwara
PHARMACEUTICALS (2014)
Role of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: a review
Prerna Mewawalla et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2014)
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Waleed Haso et al.
BLOOD (2013)
Inflammatory cytokine measurement quickly discriminates gram-negative from gram-positive bacteremia in pediatric hematology/oncology patients with septic shock
Xiao-Jun Xu et al.
INTENSIVE CARE MEDICINE (2013)
Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia
David S. Ritchie et al.
MOLECULAR THERAPY (2013)
CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo
De-Gang Song et al.
BLOOD (2012)
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning
Hollie J. Pegram et al.
BLOOD (2012)
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
Brian G. Till et al.
BLOOD (2012)
Hemophagocytic lymphohistiocytosis: updates and evolving concepts
Kimberly Risma et al.
CURRENT OPINION IN PEDIATRICS (2012)
OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells
Andreas A. Hombach et al.
ONCOIMMUNOLOGY (2012)
BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity
Leonard T. Heffner et al.
BLOOD (2012)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial
Renier Brentjens et al.
MOLECULAR THERAPY (2010)
Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
Michael C. Milone et al.
MOLECULAR THERAPY (2009)
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
Brian G. Till et al.
BLOOD (2008)
T-cell activation by recombinant immunoreceptors:: Impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells
C Heuser et al.
GENE THERAPY (2003)
Share Paper
